Willy Urassa

Willy Urassa

Auto-generated profile, based on publicly available information

Willy Urassa

World Health Organisation (WHO), Geneva, Switzerland

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 January 2019 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
AHAnnelies Van Den Heuvel
Annelies Van Den Heuvel
HSHilde Smet
Hilde Smet
IPIrena Prat
Irena Prat
ASAnita Sands
Anita Sands
WUWilly Urassa
Willy Urassa
TCTania Crucitti
Tania Crucitti
Sexually transmitted infections, such as HIV and syphilis, are one of the major health care problems worldwide, especially in low- and middle income countries. HIV screening programmes have been widely used for many years. The introduction of rapid point-of-care tests (RDTs) that can detect both HIV and syphilis, using one single blood specimen, would be a promising tool to integrate the detection of syphilis into HIV programmes and so improve the accessibility of syphilis testing and treatment. As part of the World Health Organization pre-qualification of in vitro diagnostics assessment, the laboratory performance of four dual HIV-Syphilis rapid diagnostic tests (SD Bioline HIV/Syphilis Duo, DPP HIV-Syphilis Assay, Multiplo Rapid TP/HIV Antibody Test and Insti Multiplex HIV-1/HIV-2/Syphilis Antibody Test) was assessed using a well characterized multiregional panel of stored sera specimens. In total 400 specimens were tested with each assay, resulting in excellent sensitivities and specificities for HIV, ranging from 99.5 to 100% and from 93.5 to 99.5%, respectively. Results obtained for the Treponema pallidum antibodies were lower, with the lowest sensitivity of 73.5% for Multiplo and the highest of 87% for SD Bioline. Specificities ranged from 99.0 to 100%. Although these results suggest that the tests could further improve in accuracy in detection of treponemal antibodies, their introduction into screening programmes to increase the accessibility of HIV/Syphilis diagnosis and treatment for difficult to reach populations in the world is promising.

12 August 2002 in Journal of Medical Virology
Verified
Journal Article
Closed access
PDF file
MEMalin Enbom
Malin Enbom
WUWilly Urassa
Willy Urassa
CMCharles Massambu
Charles Massambu
RTRigmor Thorstensson
Rigmor Thorstensson
FMFred Mhalu
Fred Mhalu
ALAnnika Linde
Annika Linde

19 November 2008 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
WUW Urassa
W Urassa
CMC Moshiro
C Moshiro
GCG Chalamilla
G Chalamilla
FMF Mhalu
F Mhalu
ESE Sandstrom
E Sandstrom
Youth have been reported to be at a higher risk of acquiring STIs with significant adverse health and social consequences. Knowledge on the prevailing risky practices is an essential tool to guide preventive strategies.

1 January 2008 in BMC Research Notes
Verified
Journal Article
Open access
PDF file
WUWilly Urassa
Willy Urassa
FMFerdinand Mugusi
Ferdinand Mugusi
EVEduardo Villamor
Eduardo Villamor
GMGernard Msamanga
Gernard Msamanga
CMCandida Moshiro
Candida Moshiro
WFWafaie Fawzi
Wafaie Fawzi
The United Republic of Tanzania is one of the 22 high M. tuberculosis burden countries. Data collected between 2002 and 2007 indicate that the global prevalence of drug-resistant M. tuberculosis including MDR vary greatly. The varied drug-resistance patterns make continuous surveillance of drug resistance an essential component of tuberculosis control program. M. tuberculosis isolates were obtained from consenting adult tuberculosis patients involved in a placebo-controlled study to evaluate the efficacy of multivitamin supplements on response to anti-Tb treatment in Dar es Salaam, Tanzania. Antimicrobial susceptibility testing was done on four antimicrobial agents namely streptomycin, isoniazid, ethambutol and rifampicin. HIV testing and CD4+ T lymphocytes enumeration were also done. A total of 280 M. tuberculosis isolates from 191 (68%) males and 89 (32%) female patients with no previous history of anti-tuberculosis treatment exceeding 4 weeks in the previous 12 months were tested. Among these, 133 (47%) patients were HIV seropositive. Fourteen (5.0%) isolates were resistant to any of the anti-tuberculosis drugs. The prevalence of primary resistance was 5.0%, 0.7%, 0.4% and 0% for isoniazid, streptomycin, rifampicin and ethambutol respectively. One isolate (0.4%) was MDR, with resistance to isoniazid, streptomycin and rifampicin. M. Tb primary resistance rate in a selected population in Dar es Salaam Tanzania is low and efforts should be undertaken to support the Tuberculosis program.